Loading
Duration of response measures how long a tumour that shrank stays shrunk before growing again; disease control rate adds patients whose cancer stayed stable to those who responded. Together with response rate they describe a drug's activity in trials without a comparison group.
Median DoR is required alongside objective response rate for accelerated approvals because a high response rate that lasts two months is worth little; durable responses (ongoing at 12 months or more) are the hallmark of immunotherapy and of oncogene-targeted drugs in addicted tumours. Disease control rate (CR + PR + stable disease) is a weaker measure because stable disease may reflect slow natural history rather than drug effect, and clinical benefit rate (usually stable disease ≥6 months) is used in endocrine therapy trials of breast cancer where stability is meaningful. Time to response matters clinically for symptomatic patients and is fast for chemotherapy and kinase inhibitors, slower for immunotherapy.
Shares Complete response (CR) and partial response (PR), RECIST, Progression-free survival (PFS).
Shares RECIST, Objective response rate (ORR), Progression-free survival (PFS).
Shares Objective response rate (ORR), Accelerated approval, Progression-free survival (PFS).
Shares RECIST, Progression-free survival (PFS).
Shares Objective response rate (ORR), Progression-free survival (PFS).
Shares RECIST, Objective response rate (ORR).
Shares RECIST, Progression-free survival (PFS).
Shares RECIST, Progression-free survival (PFS).